JP2023548556A5 - - Google Patents

Info

Publication number
JP2023548556A5
JP2023548556A5 JP2023527029A JP2023527029A JP2023548556A5 JP 2023548556 A5 JP2023548556 A5 JP 2023548556A5 JP 2023527029 A JP2023527029 A JP 2023527029A JP 2023527029 A JP2023527029 A JP 2023527029A JP 2023548556 A5 JP2023548556 A5 JP 2023548556A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
tcr
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023527029A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023548556A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/058019 external-priority patent/WO2022098845A1/en
Publication of JP2023548556A publication Critical patent/JP2023548556A/ja
Publication of JP2023548556A5 publication Critical patent/JP2023548556A5/ja
Pending legal-status Critical Current

Links

JP2023527029A 2020-11-05 2021-11-04 Egfr抗原を標的とする操作されたt細胞受容体および使用方法 Pending JP2023548556A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063110116P 2020-11-05 2020-11-05
US63/110,116 2020-11-05
PCT/US2021/058019 WO2022098845A1 (en) 2020-11-05 2021-11-04 Engineered t cell receptors targeting egfr antigens and methods of use

Publications (2)

Publication Number Publication Date
JP2023548556A JP2023548556A (ja) 2023-11-17
JP2023548556A5 true JP2023548556A5 (enExample) 2024-11-12

Family

ID=81458279

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023527029A Pending JP2023548556A (ja) 2020-11-05 2021-11-04 Egfr抗原を標的とする操作されたt細胞受容体および使用方法

Country Status (6)

Country Link
US (1) US20240009241A1 (enExample)
EP (2) EP4570256A3 (enExample)
JP (1) JP2023548556A (enExample)
KR (1) KR20230104220A (enExample)
CA (1) CA3200661A1 (enExample)
WO (1) WO2022098845A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116457371A (zh) * 2020-10-07 2023-07-18 多安生物治疗有限公司 T细胞受体、包含t细胞受体的免疫细胞及其使用方法
WO2024054863A1 (en) * 2022-09-06 2024-03-14 Board Of Regents, The University Of Texas System T-cell receptor that targets egfr mutation and methods of using the same
WO2024123794A2 (en) * 2022-12-05 2024-06-13 Board Of Regents, The University Of Texas System A t cell receptor recognizing a her2 mutation presented on hla-a*02:01 and methods of use
WO2026011097A1 (en) * 2024-07-03 2026-01-08 Yale University Antibody drug conjugates comprising tcr-vbeta specific therapeutic molecules and uses thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
NL8200523A (nl) 1982-02-11 1983-09-01 Univ Leiden Werkwijze voor het in vitro transformeren van planteprotoplasten met plasmide-dna.
US4952500A (en) 1988-02-01 1990-08-28 University Of Georgia Research Foundation, Inc. Cloning systems for Rhodococcus and related bacteria
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5302523A (en) 1989-06-21 1994-04-12 Zeneca Limited Transformation of plant cells
US5550318A (en) 1990-04-17 1996-08-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US7705215B1 (en) 1990-04-17 2010-04-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US5322783A (en) 1989-10-17 1994-06-21 Pioneer Hi-Bred International, Inc. Soybean transformation by microparticle bombardment
US5484956A (en) 1990-01-22 1996-01-16 Dekalb Genetics Corporation Fertile transgenic Zea mays plant comprising heterologous DNA encoding Bacillus thuringiensis endotoxin
US5384253A (en) 1990-12-28 1995-01-24 Dekalb Genetics Corporation Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US5610042A (en) 1991-10-07 1997-03-11 Ciba-Geigy Corporation Methods for stable transformation of wheat
ATE398679T1 (de) 1992-07-07 2008-07-15 Japan Tobacco Inc Verfahren zur transformation einer monokotyledon pflanze
US5702932A (en) 1992-07-20 1997-12-30 University Of Florida Microinjection methods to transform arthropods with exogenous DNA
JP2952041B2 (ja) 1992-07-27 1999-09-20 パイオニア ハイ−ブレッド インターナショナル,インコーポレイテッド 培養ダイズ細胞のagrobacterium媒介形質転換の改良法
GB9222888D0 (en) 1992-10-30 1992-12-16 British Tech Group Tomography
US5656610A (en) 1994-06-21 1997-08-12 University Of Southern California Producing a protein in a mammal by injection of a DNA-sequence into the tongue
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5780448A (en) 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
US5945100A (en) 1996-07-31 1999-08-31 Fbp Corporation Tumor delivery vehicles
US5981274A (en) 1996-09-18 1999-11-09 Tyrrell; D. Lorne J. Recombinant hepatitis virus vectors
CA2277278A1 (en) 1997-01-10 1998-07-16 Life Technologies, Inc. Embryonic stem cell serum replacement
JP2001523958A (ja) 1997-03-21 2001-11-27 ブライハム アンド ウィミンズ ホスピタル,インコーポレイテッド 免疫療法のctla−4結合ペプチド
US5994624A (en) 1997-10-20 1999-11-30 Cotton Incorporated In planta method for the production of transgenic plants
CZ302706B6 (cs) 1998-12-23 2011-09-14 Pfizer Inc. Lidská monoklonální protilátka, farmaceutická kompozice tuto protilátku obsahující, bunecná linie produkující tuto protilátku, izolovaná molekula kódující težký nebo lehký retezec uvedené protilátky, hostitelská bunka obsahující tuto izolovanou molek
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
CN101970499B (zh) 2008-02-11 2014-12-31 治疗科技公司 用于肿瘤治疗的单克隆抗体
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
WO2010014784A2 (en) 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
JP2012500855A (ja) 2008-08-25 2012-01-12 アンプリミューン、インコーポレーテッド Pd−1アンタゴニストおよび感染性疾患を処置するための方法
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
JP2014022858A (ja) 2012-07-17 2014-02-03 Murata Mfg Co Ltd 電力増幅器
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
CN112552401B (zh) 2013-09-13 2023-08-25 广州百济神州生物制药有限公司 抗pd1抗体及其作为治疗剂与诊断剂的用途
US11203783B2 (en) * 2013-11-21 2021-12-21 Repertoire Genesis Incorporation T cell receptor and B cell receptor repertoire analysis system, and use of same in treatment and diagnosis
EP3177643B1 (en) 2014-08-04 2019-05-08 F.Hoffmann-La Roche Ag Bispecific t cell activating antigen binding molecules
EP3916018A1 (en) 2015-06-16 2021-12-01 Genentech, Inc. Anti-cd3 antibodies and methods of use
KR20180118175A (ko) * 2016-03-04 2018-10-30 노파르티스 아게 다중 키메라 항원 수용체 (car) 분자를 발현하는 세포 및 그에 따른 용도
MX2019003768A (es) * 2016-10-03 2019-06-24 Juno Therapeutics Inc Moleculas de enlace especificas de hpv.
US20210147550A1 (en) * 2017-08-18 2021-05-20 Joshua Michael Francis Antigen-binding proteins targeting shared antigens
US20220175899A1 (en) * 2019-04-11 2022-06-09 The Board Of Trustees Of The Leland Stanford Junior University Cytotoxic t lymphocytes specific for mutated forms of epidermal growth factor receptor for use in treating cancer
CN111848782A (zh) * 2019-04-25 2020-10-30 天津亨佳生物科技发展有限公司 一种针对egfr l858r基因突变的特异性t细胞受体及其应用
EP3962939A4 (en) * 2019-05-03 2023-05-17 Gigamune, Inc. MODIFIED CELLS EXPRESSING ANTITUMOR T-LYMPHOCYTE RECEPTORS AND METHODS OF USING THEM

Similar Documents

Publication Publication Date Title
JP2023548556A5 (enExample)
US10118964B2 (en) Construction and application of bispecific antibody HER2xCD3
JP7595696B2 (ja) Cd3抗原結合性断片及びその使用
US9777073B2 (en) Construction and application of bispecific antibody EpCAM×CD3
CN106967172B (zh) 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途
JP2022058776A (ja) 系統特異的抗原の阻害のための組成物および方法
JP2023528255A5 (enExample)
CN104592392B (zh) 一种双特异性抗体EpCAM×CD3的构建及应用
CN106397593A (zh) 抗磷脂酰肌醇蛋白多糖‑3的抗体及其应用
CN118580363A (zh) 制导和导航控制蛋白及其制备和使用方法
CN104592391B (zh) 一种双特异性抗体EpCAM×CD3的构建及应用
CN112794909A (zh) 一种抗tigit单克隆抗体及其应用
CN104788567A (zh) 一种靶向鼠T淋巴细胞CD3和人肿瘤抗原EpCAM的双特异性抗体制备方法及应用
CN109705225B (zh) 一种抗人caix抗原的嵌合抗原受体及其应用
CN104829725A (zh) 一种双特异性抗体cd133×cd3的构建及应用
KR20210132668A (ko) 인공 면역감시 키메라 항원 수용체(ai-car) 및 이를 발현하는 세포
WO2023051414A1 (zh) 靶向间皮素的抗体及其用途
CN111848806B (zh) Egfr-cd3双功能抗体及其应用
CN104288765A (zh) 一种利用具有中和FLT3生物学活性的McAb应用于肿瘤的靶向治疗的新方法
JP2023530245A5 (enExample)
CN111434691A (zh) Pd-l2单克隆抗体及其应用
CN103965359B (zh) 抗上皮细胞粘附分子和t细胞抗原的双特异性抗体
CN117924519A (zh) 靶向cd138的嵌合抗原受体
CN118126194A (zh) 靶向cd70的嵌合抗原受体
US20240050567A1 (en) Modified immune effector cell and use thereof